Details

Last Funding Type

Post-IPO Debt

Last Funding Money Raised

€20M

Industries

Biotechnology,Health Care,Information Technology

Founded date

Jan 1, 2003

Number Of Employee

11 - 50

Operating Status

Active

BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment of multiple sclerosis. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative flu vaccine. BiondVax’s team of 14 includes scientists, technicians, researchers, and administrative staff. The company’s state-of-the-art GMP facility in Ness-Ziona houses its laboratories, production facilities and offices.